Allergan is currently the subject of much speculation as Valeant Pharmaceuticals looks to acquire it. Valeant Pharmaceuticals, well known for building its company via acquisitions, put in a $46 billion bid one week ago to acquire Californian based botox maker Allergan.
Allergan however doesn’t seem to be interested in the bid and has met it with hostility. Industry analysts believe that Allergan doesn’t think the bid is high enough and will demand a higher price, and that Valeant must up its bid in order to complete the deal.
In the meantime now that Allergan knows it is being seen as a possible acquisition target for some of the big pharma companies and isn’t happy with the offering price from Valeant it has reportedly approached both J&J and Sanofi to see if either of them would be interested in buying them for a higher value.
If this wasn’t enough to deter Valeant, Allergan has also showed signs of interest in Ireland based Shire Pharmaceuticals for a possible takeover; a move that if completed would hopefully make them too large for acquisition by Valeant.
We will have to see whether Valeant significantly increases its bid to avoid Allergan being scooped up by another big pharma company willing to pay a higher price for it.
Other deals and news in recent days amongst big pharma companies include:
- Novartis and GlaxoSmithKline entering a joint venture for consumer health
- Sanofi seeking to dispose of mature product portfolio
- BMS has entered into m&a for $725 million
- AstraZeneca rejects Pfizer’s takeover offer
- J&J forms pharma alliance with ACSM
- Novartis and GlaxoSmithKline to exchange assets in the fields of oncology and vaccines
These and other recent deals continue the theme of consolidation and specialization taking place amongst the top pharma companies as they seek to focus resources to maximize return on R&D investment.
Report: Merger and Acquisition Terms and Agreements
Report Partnering Agreements with Valeant 2009-2014
Report: Partnering Agreements with Allergan 2009-2014